Provided is the use of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin) for weight management, decreasing food intake, and inducing satiety in a therapeutic setting with consideration of the patient&rsquos renal function. It has been determined that patients with severe renal impairment or end stage renal disease (ESRD) are exposed to greater levels of lorcaserin metabolites following administration of the agent and so the use of lorcaserin in these patients appears to be contraindicated. Further provided are low dose formulations of lorcaserin.
